Abstract
The role of antiplatelet agents in stroke prevention is well documented, especially for secondary prevention, but many patients with no previous stroke but with other risk factors (high cardiovascular risk, women with diabetes mellitus, chronic kidney disease, peripheral artery disease, or asymptomatic carotid stenosis) can also benefit. The findings of Jung et al.1 are therefore clinically relevant and can be used to reassure patients that even if antiplatelet agents fail to prevent stroke, they can mitigate its severity. Although it is an observational study, a randomized trial to test the effect of antiplatelet agents on ischemic stroke severity might not be ethically acceptable.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
